Name: PMS and PMDD: Lifestyle First, Medication for the Severe End, and the Psychedelic Question Honestly
Creator: Realised
Published: 2026-06-01

Summary

PMS and PMDD are best managed by SEVERITY, not by a reflex reach for a pill: for mild-to-moderate PMS the first line is the low-risk, evidence-anchored lifestyle tier (CBT, aerobic exercise, calcium ~1200 mg/day, sleep and luteal diet tweaks), escalating to medication only if that fails over two to three cycles; for severe, DSM-recognised PMDD an SSRI (continuous or luteal-only) and/or a drospirenone pill are genuine guideline first-line alongside CBT, because it is a serious disorder with elevated suicidality, but the SSRI story deserves honesty (it works in ~60-70%, fails in ~40%, placebo ru

Why Moderate

Moderate Evidence for the entry as a whole: it blends strong anchors (DSM-5 recognition, the Cochrane SSRI synthesis, government B6 pharmacovigilance) with moderate ones (CBT, exercise, the ageing calcium RCT) and genuinely weak-to-experimental ones (chasteberry; psilocybin and microdosing). The directions are well supported; the magnitudes and the frontier options are not uniformly strong.

NOT Strong for the headline because the management ladder mixes a strong SSRI/recognition anchor with moderate lifestyle levers, a single-flagship calcium result, and an explicitly experimental psychedelic frontier.

NOT Emerging because the core (PMDD as a formal diagnosis, the Cochrane-synthesised SSRI effect, the B6 harm, the severity-gated stepped-care guidelines) is established, not suggestive.

The per-lever split (read this, not just the headline):
• PMDD is real / recognition & prevalence: Strong, DSM-5 plus epidemiology.
• Stepped care (lifestyle-first for mild-moderate; medication first-line for severe): Strong, ACOG/RCOG/ISPMD concordant.
• SSRIs (efficacy): Strong for the lever, but ~40% non-response and high placebo, and the mechanism is neurosteroid not serotonin.
• CBT: Moderate, meta-analytic, modest, heterogeneous.
• Exercise: Moderate, effect probably inflated by small-trial bias.
• Calcium: Moderate, one large 1998 RCT plus small replications.
• Evening primrose oil: Null. Chasteberry: Uncertain. High-dose B6 harm: Strong.
• Psilocybin for PMDD: Experimental, zero completed trials. Microdosing: Experimental / largely placebo.

Practical takeaway

The framing to hold: manage by severity. Take PMDD seriously, and match the intensity of the treatment to the intensity of the condition. For most premenstrual distress the first line is lifestyle and behavioural; for severe PMDD, medication and CBT are appropriately first-line and should not be delayed.

Step 0, always: get the diagnosis right (PMS vs PMDD). PMS is common and mild-to-moderate; PMDD is severe, impairing, and confined to the luteal phase with a symptom-free stretch after menstruation. The defining feature is timing plus severity, ideally confirmed by prospectively tracking symptoms across two cycles. If premenstrual symptoms disrupt work, relationships, or safety, that is a clinical conversation, not a supplement question.

For mild-to-moderate PMS: the lifestyle-and-behavioural tier is first line.
• CBT and regular aerobic exercise are the best-supported non-drug levers, both guideline-endorsed.
• Calcium ~1200 mg/day, from food where possible is the one credible supplement, a low-risk adjunct. Prefer dietary calcium; if supplementing, use a small split dose with food. Form, absorption, food sources and the food-versus-supplement question are owned by calcium_food_vs_supplement_and_absorption.
• Sleep, and luteal-phase diet tweaks (steady complex carbs, cutting back on caffeine, alcohol, and salt in the premenstrual window) are reasonable, low-risk, common-sense foundations.
• Optional Emerging add-ons, not anchors: magnesium (better with B6 at safe doses), bright light therapy, vitamin D. Chasteberry is uncertain and carries interaction caveats.
• Escalate to an SSRI (ideally luteal dosing) or a drospirenone combined pill if this tier fails over two to three tracked cycles.

For severe, DSM-recognised PMDD: medication and CBT are first-line, do not delay.
• An SSRI (continuous or luteal-phase) and/or a combined oral contraceptive are guideline first-line, with CBT as a genuine co-first-line, not a stalling tactic. Withholding effective treatment behind a long lifestyle trial in severe disease is a real harm, given the suicidality risk.
• Carry the SSRI honestly: it helps about 60-70% and fails about 40%, placebo response is high, side effects (sexual dysfunction, weight, discontinuation) are real, and there is a black-box suicidality caution under 25 that argues for close monitoring in young people. Luteal-only dosing is worth discussing to cut the off-week burden.
• Keep the lifestyle tier layered underneath, not abandoned: exercise, sleep, and CBT still help alongside medication.

On the psychedelic question, honestly.
• Psilocybin is an experimental frontier for PMDD, with no completed trials, an Emerging (and caveated) depression evidence base, Schedule-I status, and real contraindications (personal or family history of psychosis or bipolar disorder, cardiac disease, SSRI interaction, and the need for supervised set and setting). It is appropriate only inside a registered trial, not as a self-directed swap for medication.
• Microdosing is, on the best-blinded evidence, largely placebo, with no PMDD data. Do not rely on it as a treatment.

Do NOT reach first for the herbal aisle, and do NOT take high-dose B6. Evening primrose oil is null, "hormone-balancing" teas are unsupported, and the high supplemental B6 doses sold for PMS carry a genuine nerve-damage risk (food and multivitamin-level B6 is fine).

The boundary that governs all of this. PMDD is a psychiatric diagnosis. Severe, impairing, or safety-relevant premenstrual symptoms warrant clinical assessment and, usually, prescription treatment. This entry names the levers and their order; a clinician chooses and monitors them.

Evidence detail

Why This Entry Exists

Three errors fire around premenstrual symptoms, not two. The first dismisses them ("she's just moody", "everyone gets PMS", "toughen up"). The second over-sells the natural fix (an aisle of evening primrose oil, chasteberry, high-dose B6, and "hormone-balancing" teas). And the third, subtler one is a reasoning shortcut in the other direction: "I have bad PMS, so I need an SSRI", jumping straight to a daily psychiatric drug (with real side effects and, for young people, a suicidality black box) past the lower-risk levers that should be tried first for the milder end. All three are wrong.

The honest picture is a severity-gated ladder. PMDD is a distinct, severe condition the American Psychiatric Association moved into the main text of DSM-5 in 2013 as a depressive disorder; under strict criteria it affects roughly 2 to 5% of menstruating people (broader estimates run to ~8% depending on the criteria used), and it carries elevated suicidal ideation. That end of the spectrum genuinely warrants first-line medication and CBT, and delaying effective treatment behind a long lifestyle trial there is its own harm. But most premenstrual distress is mild-to-moderate PMS, and for that the guideline-endorsed first move is behavioural and lifestyle, not a prescription. The mistake the entry protects against is collapsing that ladder in either direction: neither "just tough it out" nor "everyone with PMS needs a pill".

And because the psychedelic conversation is now loud, this entry says plainly where psilocybin and microdosing actually sit: mechanistically interesting, genuinely under-researched because of illegal status, but currently experimental (psilocybin) or mostly-placebo (microdosing) for this use, not a ready alternative.

What bad advice this protects against, in all directions:
• "PMDD is just being moody / hormonal, get over it" → false and harmful. PMDD is a DSM-5 depressive disorder (~2 to 5% prevalence) with elevated suicidality; dismissing it delays effective care.
• "I have bad PMS, so I need an SSRI" → a massive jump for the milder end. For mild-to-moderate PMS the first line is lifestyle and CBT, escalating to medication only if those fail; SSRIs are appropriately first-line for SEVERE PMDD, not for every premenstrual complaint, and the black-box suicidality caution under 25 makes the jump especially costly in young people.
• "An SSRI fixes your low serotonin" → wrong mechanism. PMDD is not a serotonin deficiency; SSRIs work here via a rapid boost to the neurosteroid allopregnanolone (a GABA-A modulator), which is why they act in days not weeks and can be dosed luteally. Effective, but not for the reason the "chemical imbalance" story implies.
• "Just take evening primrose oil / high-dose B6 / a hormone-balancing tea" → mostly unsupported or unsafe. EPO is essentially null in good trials; high-dose B6 causes nerve damage; teas have no credible evidence.
• "Psilocybin / microdosing is the natural alternative to antidepressants" → outruns the evidence. There are zero completed psilocybin trials for PMDD, the depression evidence is Emerging with real caveats, and controlled microdosing studies point to placebo. Interesting frontier, not a current recommendation.

This entry owns the severity-gated PMS/PMDD management ladder, the honest read on SSRIs (mechanism, response rate, side effects, luteal dosing, young-person caution), the evidence-based lifestyle-first tier, the supplement debunks, and the honest placement of the psychedelic frontier. It defers cycle physiology to menstrual_cycle_health_and_menopause, exercise-for-mood dosing to exercise_for_mood_dose_response, and the psilocybin/microdosing clinical detail to psilocybin_assisted_therapy_clinical and menopause_microdosing.

Evidence

Organised by lever, tier signal inline. The strongest anchors are independent (DSM-5, Cochrane, government pharmacovigilance, and independent placebo-controlled psychedelic work). Read the per-finding signals, not just the thesis.

PMDD is a recognised, severe condition, not "just moody" (Strong Evidence for the recognition/prevalence facts).

1. PMDD is a DSM-5 depressive disorder, ~2 to 5% prevalent, with elevated suicidality. PMDD was moved into the main text of DSM-5 in 2013 as a depressive disorder, having previously sat only in the DSM-IV appendix. Under strict DSM-5 criteria it affects roughly 2 to 5% of menstruating people, with broader estimates up to ~8% depending on criteria and ascertainment, and it is associated with elevated suicidal ideation. This is authoritative nosology plus epidemiology. (Epperson CN, Steiner M, Hartlage SA, et al. Am J Psychiatry. 2012;169(5):465-475, PMC3462360; APA DSM-5, 2013; suicidality summarised in PMC8832802. Strong for the recognition/prevalence facts, no supplement-industry interest.)

The lifestyle-and-behavioural tier, first-line for mild-to-moderate PMS (Moderate Evidence).

2. CBT reduces premenstrual symptoms with modest but durable effect. A systematic review and RCTs (individual and couple-delivered) show CBT lowers total premenstrual symptoms and distress versus waitlist, with effect sizes comparable to antidepressants in shared syntheses (roughly d 0.24 to 0.70) and better durability at follow-up. It is guideline-endorsed and has no commercial conflict. (Lustyk MKB, et al. Arch Womens Ment Health. 2009, PubMed 19247573; Ussher/Perz couple-CBT RCT, PMC5395168; Busse JW, et al. Psychother Psychosom. 2009;78(1):6-15, PubMed 18852497. Moderate, meta-analytic, small waitlist-controlled trials, quality rated low, so read the durability generously.)

3. Aerobic exercise helps, though the effect size is probably inflated. A meta-analysis of 15 RCTs (n=717) found a large pooled reduction in global PMS symptoms (SMD around −1.08, 95% CI −1.88 to −0.29), but with high heterogeneity and small, low-quality trials, so the true effect is likely smaller than the headline. Still a low-risk, high-upside first-line lever. Dosing detail is owned by exercise_for_mood_dose_response. (Exercise-for-PMS meta-analysis, PMC7465566. Moderate, likely magnitude-inflated by small-trial bias.)

4. Calcium carbonate 1200 mg/day beat placebo, the best-supported single supplement. In a randomised, double-blind, placebo-controlled multicentre trial (466 evaluable), calcium carbonate 1200 mg/day reduced premenstrual symptoms over three cycles, echoed by smaller later RCTs. The caveats: the flagship trial is from 1998, and calcium is heavily vendor-promoted, so marketing outruns the (real but modest, ageing) evidence. (Thys-Jacobs S, et al. Am J Obstet Gynecol. 1998;179(2):444-452; replication PMC5313351, 2017. Moderate, one large positive RCT plus small replications; cheap and low-risk, but old.)

SSRIs, honest teardown, first-line for SEVERE PMDD not for everyone (Strong for efficacy, with a ~40% failure fraction).

5. SSRIs have a moderate pooled effect, work in ~60-70% and fail in ~40%, and luteal dosing is a real option. A Cochrane review (updated CD001396) found a moderate effect over placebo (standardised mean difference −0.57, 95% CI −0.72 to −0.42), with moderate-dose more effective than low-dose. But the honest reading is "effective but not enough": roughly 60-70% respond, about 30% respond to placebo, and around 40% do not respond to the drug. Continuous dosing is at most slightly better than luteal (premenstrual-only) dosing for mood, and luteal dosing works (SMD −0.39, 95% CI −0.58 to −0.21, 6 studies) while reducing the off-week side-effect burden, though it is less effective for somatic symptoms. (Jespersen C, et al. Cochrane Database Syst Rev, CD001396 pub4 (2024), the 34-RCT update of Marjoribanks 2013 pub3; Reilly TJ, et al. intermittent-SSRI meta-analysis, J Psychopharmacol. 2023, PMC10074750; Pearlstein "effective but not enough", PubMed 18622361. Strong for the lever, Cochrane synthesis, but the net responder fraction is modest and the trial base includes pharma-sponsored studies.)

6. SSRIs carry real side effects and a young-person suicidality caution. The common and often persistent adverse effects in this use are sexual dysfunction and reduced libido, with weight gain on longer-term use, plus nausea, reduced energy, sleep disturbance, and a genuine discontinuation/withdrawal syndrome (worse with short-half-life agents). Luteal dosing partly mitigates the sexual-dysfunction, weight, and discontinuation load by leaving off-weeks drug-free. And the antidepressant class carries an FDA black-box warning for increased suicidal ideation in people under 25 (pooled trial data show ideation roughly 2% to 4% versus placebo in youth). This is a load-bearing reason to try lower-risk steps first in young people and to monitor closely, not a reason to withhold effective treatment in severe disease. (FDA black-box, summarised Mayo Clinic and PMC12854806; SSRI-for-PMS AE profile, PMC7073417 and ge-bu.nl review. Strong for the AE/regulatory facts.)

The supplement aisle, mostly weak-to-null-to-harmful.

7. Evening primrose oil is essentially null; chasteberry is weak-to-uncertain; high-dose B6 causes nerve damage. Good-quality trials show no significant EPO effect over placebo, despite it being one of the most-sold PMS remedies. Chasteberry (Vitex) has a positive signal (a meta-analysis of 3 RCTs, n=520, remission OR ~2.57) but systematic reviews flag high risk of bias, heterogeneity and probable publication bias, so it is at best exploratory and carries herb-hormone interaction concerns. And high-dose pyridoxine (B6) causes a dose-dependent sensory peripheral neuropathy: regulators now trigger warnings above roughly 10 mg/day (Australia), neuropathy is reported below 50 mg in susceptible people, and the RDA is only ~1.3 to 2 mg, so the megadoses marketed for PMS are a real harm while food and multivitamin-level B6 is fine. (Whelan AM, et al. herbal-PMS systematic review, 2009, DARE NBK77752 (EPO null); Verkaik S, et al. Vitex meta-analysis 2017, and van Die MD, et al. Planta Med. 2013, PubMed 23136064 (chasteberry bias); TGA safety review 2022 + Medsafe NZ 2025 + PMC10343656 (B6 neuropathy). Strong for the B6 harm and the EPO null; chasteberry Uncertain.)

The psychedelic frontier, honestly placed (Experimental, and mostly-placebo for microdosing).

8. Psilocybin has zero completed PMDD trials and only Emerging depression evidence, so it is Experimental for this use. No completed clinical trial of psilocybin for PMS/PMDD exists; two early microdosing trials have only just registered, with no results. The adjacent depression evidence is genuinely emerging but caveated: the COMPASS COMP360 phase-2b trial (Goodwin et al., NEJM 2022) found single-dose 25 mg beat 1 mg on depression score at week 3 (about a 6.6-point MADRS difference) with rapid onset, but the benefit narrowed by week 12 and serious adverse events including suicidal ideation occurred (more in the high-dose arm), and it was company-funded. The widely-cited psilocybin-versus-escitalopram trial (Carhart-Harris et al., NEJM 2021) actually did NOT beat the SSRI on its pre-registered primary endpoint, so the "psilocybin beats antidepressants" headline overstates it. There is a real mechanistic hook for a sex-hormone interaction (in rodents, the 5-HT2A head-twitch response to psychedelics is larger in females and estrogen-modulated), but that is preclinical, and cyclical/luteal psilocybin dosing for PMDD is entirely unstudied. Schedule-I status is the primary reason for the trial gap. Deep clinical detail lives in psilocybin_assisted_therapy_clinical. (Goodwin GM, et al. NEJM 2022, NEJMoa2206443; Carhart-Harris R, et al. NEJM 2021, NEJMoa2032994, plus Bayesian reanalysis PMC10278160; estrogen-5-HT2A preclinical, PMC12261225. Experimental for PMDD, Emerging for depression.)

9. Microdosing is mostly placebo in the best-blinded studies. The largest placebo-controlled microdosing study (Szigeti et al., 2021, eLife, self-blinding, n=191) found microdose and placebo groups both improved on wellbeing with no significant difference between them, and participants' belief about what they took predicted outcomes better than what they actually took. A double-blind study (Cavanna et al., 2022) reached the same conclusion: effects tracked expectancy, with acute effects stronger only among those who correctly guessed they got the active dose. There is no PMDD-specific microdosing evidence. Honest verdict: the claimed benefits are largely expectancy, which is a striking counterpoint to the "SSRIs are just placebo" argument. Detail in menopause_microdosing. (Szigeti B, et al. eLife 2021 (self-blinding); Cavanna F, et al. Sci Rep 2022; Polito & Liknaitzky J Psychopharmacol 2024. Experimental / largely placebo.)

Mechanism

Why PMDD is a sensitivity disorder, not a hormone excess. People with PMDD generally have normal ovarian hormone levels. The current model is abnormal SENSITIVITY: mood and GABA-ergic circuitry in a subset of people reacts atypically to the normal luteal-phase fall in progesterone and its neuroactive metabolite allopregnanolone (a positive modulator of GABA-A receptors), producing severe affective symptoms in the premenstrual window. "She's just hormonal" misses the point: the problem is the nervous system's response to ordinary hormonal cycling.

Why "SSRIs fix low serotonin" is the wrong story, and why they can be dosed luteally. In depression SSRIs take weeks. In PMDD they often act within a day or two, which is incompatible with the slow synaptic-remodelling account. The favoured mechanism is that SSRIs rapidly upregulate 3-alpha-hydroxysteroid dehydrogenase, the enzyme that makes allopregnanolone, boosting GABA-A tone independent of serotonin reuptake, on the same neurosteroid axis targeted by brexanolone and zuranolone. That rapid, neurosteroid-mediated action, not a corrected serotonin deficit, is why luteal-phase-only dosing works: start when symptoms are due and get benefit inside the same premenstrual window. This remains the leading hypothesis rather than settled fact, and an acute-serotonin contribution may also play a part, but the "chemical imbalance" framing is not supported as the operative mechanism.

Why the psychedelic mechanism is a different axis, and unproven here. Psilocybin acts through 5-HT2A agonism and acute neuroplasticity, a different lever from the GABA-A/allopregnanolone axis SSRIs exploit in PMDD, so a benefit cannot be assumed by analogy. The sex-hormone interaction (estrogen modulating 5-HT2A responsiveness) is real in preclinical models and makes cycle-phase effects plausible, but there is no human trial in PMDD to convert plausibility into evidence.

Why the herbal levers are weak or harmful. Evening primrose oil supplies gamma-linolenic acid on a premenstrual fatty-acid-deficit theory that good trials do not bear out. Chasteberry acts on dopaminergic/prolactin pathways, coherent but too bias-limited to size. High-dose B6 is directly toxic to sensory dorsal-root-ganglion neurons, a dose-dependent poisoning that scales with megadoses and spares food-level intake.

Risks And Contraindications

• "Lifestyle first" must NOT become "never medicate severe PMDD." For genuinely severe PMDD with functional impairment or suicidality, SSRIs/hormonal treatment and CBT are first-line, and delaying them behind a lengthy lifestyle trial is its own harm. The ladder is severity-gated, not a blanket "drugs are a last resort" rule.
• "SSRIs work for PMDD" must NOT become "everyone with PMS should be on an SSRI." They carry real adverse effects (sexual dysfunction, weight, discontinuation), fail in ~40%, and carry a young-person suicidality black box. Present them as an effective, clinician-led, severity-matched option with luteal dosing available, not a default.
• The psychedelic frontier must NOT be sold as ready. No completed PMDD psilocybin trials exist, the depression data are Emerging with real safety signals, and microdosing is mostly placebo. Present it as experimental (trial-only) and honestly-placebo respectively, never as a recommended alternative to established care, and flag the psychosis/bipolar and SSRI-interaction contraindications.
• High-dose B6 is a genuine harm, framed precisely. The neuropathy risk is about the HIGH supplemental megadoses sold for PMS, not food or standard-multivitamin B6, which is safe and necessary.
• Calcium is the strongest supplement but the flagship trial is old (1998) and vendors overstate it. A reasonable low-risk adjunct, not a cure.
• Do not drift into cycle physiology or menopause (owned by menstrual_cycle_health_and_menopause) or improvise exercise dose numbers (owned by exercise_for_mood_dose_response).
• Red-flag / see-a-clinician boundary. PMDD is associated with elevated suicidal ideation. Self-harm thoughts, suicidal thoughts, or a premenstrual mood crash severe enough to impair safety are a reason to seek urgent professional help (a GP, a mental-health service, or a crisis line), not a reason to reach for a supplement or an unsupervised psychedelic. Handle this plainly, with a signpost to care.

Controversy

Nature: a three-way tension. A dismissive default ("PMS is just moodiness") collides with an over-selling supplement market ("here's a natural, hormone-balancing fix") and, increasingly, an over-eager psychedelic narrative ("microdose instead of medicating"), while the genuinely effective, severity-matched care sits in the middle and satisfies none of the three.

Position A, "PMDD is real and severe, and for it, medication plus CBT work." The grounded take on the severe end: PMDD is a DSM-5 depressive disorder with elevated suicidality, and SSRIs (moderate Cochrane effect), combined pills, and CBT are legitimate first-line. Where it goes wrong if overstated: collapsing into "everyone with PMS should be medicated", ignoring the ~40% non-response, the high placebo rate, the side effects, and the young-person black box, and treating the serotonin-deficiency story as if it were the mechanism (it is not).

Position B, "For most premenstrual distress, lifestyle and behavioural levers come first, and the supplement aisle is weak." The corrective take on the milder end and the market: for mild-to-moderate PMS, CBT, exercise, calcium, sleep, and luteal diet tweaks are the evidence-based first line, and evening primrose oil is null, chasteberry uncertain, and high-dose B6 harmful. Where it goes wrong if overstated: implying "nothing pharmacological is needed" for severe PMDD, or that "natural" equals safe (high-dose B6 is the counterexample).

Position C, "Psychedelics are the honest alternative to antidepressants." The frontier take. Where it is right: SSRIs are imperfect, the psilocybin depression data are genuinely interesting and rapid-acting, and the illegal status really has starved the research. Where it is wrong: there are zero completed PMDD psilocybin trials, the depression evidence is Emerging with durability and suicidality caveats and a headline trial that failed its own primary endpoint, cyclical dosing is unstudied, and microdosing specifically is mostly placebo in the best-blinded studies. Promising research frontier, not a current treatment.

The funding/bias dimension, cui bono, three ways. The supplement aisle profits from the "natural and gentle" framing and from medical treatment sounding scary. The SSRI trial base includes pharma-sponsored studies, though the effect survives independent Cochrane synthesis. And the psychedelic space now has its own commercial pressure: company-funded pivotal trials (COMPASS), a growing clinic/retreat and microdosing-product market, and media incentives to over-report promise, which is exactly why the "beat SSRIs" and "microdose instead" claims need the primary-endpoint and placebo receipts attached.

Realised Position: Manage by severity. For mild-to-moderate PMS, start with the low-risk evidence-anchored lifestyle tier (CBT, exercise, calcium, sleep, luteal diet) and escalate only if it fails. For severe PMDD, an SSRI (continuous or luteal) or a combined pill plus CBT is genuine first-line and should not be delayed, while carrying the honest caveats (works in ~60-70%, neurosteroid not serotonin, real side effects, young-person black box). Treat psilocybin as an experimental, trial-only frontier and microdosing as mostly-placebo. Do not dismiss the condition, do not sell it herbs, and do not sell it psychedelics as ready either.

Cross-Pillar Connections

This is a genuinely cross-pillar topic: PMDD spans mood/mental health, women's health, movement, supplements, and the psychedelic-medicine frontier.
• Women's health (menstrual_cycle_health_and_menopause): owns the underlying cycle physiology and menopause; this entry holds only the PMS/PMDD management layer and the luteal-phase timing treatment hangs on.
• Mental / mood (anxiety_lifestyle_levers): PMDD is a depressive-spectrum disorder with prominent affective and anxiety symptoms; the general lifestyle-lever framing is the sibling read.
• Movement (exercise_for_mood_dose_response): owns the exercise-for-mood dosing; this entry only places exercise on the treatment list.
• Supplements / mood (magnesium_supplementation_depression): the same honest-appraisal method applied to a different premenstrual/mood supplement claim.
• Psychedelic medicine (psilocybin_assisted_therapy_clinical, menopause_microdosing): own the clinical psilocybin evidence and the microdosing-is-mostly-placebo read in depth; this entry only places them honestly for the PMDD question (experimental / largely placebo) and defers the detail there.
• Foundations (cui_bono_industry_funding_bias): the three-way funding read (supplement aisle, pharma, psychedelic market).

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd elevate psilocybin from Experimental for PMDD if a well-powered, placebo/active-controlled, adequately-blinded trial in PMDD specifically showed a durable benefit with an acceptable safety profile (including in the SSRI-interaction and cyclical-dosing questions that are currently unstudied).
• We'd revise the microdosing verdict if further self-blinding or double-blind trials showed a specific drug effect over expectancy (the current best evidence points the other way).
• We'd move EPO or "hormone-balancing" teas off null, or upgrade chasteberry, on a large, low-bias, independently funded positive RCT.
• We'd revise the SSRI or CBT claims if a rigorous head-to-head in PMDD-specific samples showed they fail to separate from placebo.
• We'd soften the B6 harm warning if new pharmacovigilance showed the neuropathy risk is negligible at PMS doses (current regulatory action points the other way).

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs three ways, and the entry says so all three.
• Toward the supplement aisle. Evening primrose oil, chasteberry, high-dose B6, and "hormone-balancing" teas profit from the "natural and gentle" framing, benefiting both when medical treatment is made to sound scary and when null/weak evidence goes under-reported. Some chasteberry trials involve the extract manufacturer, and the literature flags probable publication bias. High-dose B6 is pushed despite regulators warning about nerve damage.
• Toward pharma, and why it doesn't undermine the SSRI finding. The SSRI trial base includes industry-sponsored studies, a real reason for scrutiny, but the effect survives independent Cochrane synthesis, and the honest caveats (non-response, placebo, side effects, mechanism) are exactly what a seller would under-communicate and this entry foregrounds.
• Toward the psychedelic market. The pivotal psilocybin depression trial was company-funded (COMPASS), and there is a fast-growing clinic, retreat, and microdosing-product economy plus strong media incentives to over-report promise, which is why the "psilocybin beats antidepressants" claim (a trial that missed its primary endpoint) and the microdosing hype (mostly placebo when blinded) need the receipts attached.
• The net read. The most profitable options across all three markets (the herbs, and the microdosing products) are among the weakest, and the strongest safety finding (B6 neuropathy) comes from regulators with no product to sell. See cui_bono_industry_funding_bias for the general pattern.

PMS and PMDD: Lifestyle First, Medication for the Severe End, and the Psychedelic Question Honestly